SUPN
Supernus Pharmaceuticals, Inc.−$13.77 (32.85%) At close $28.15 · Tue
☾After Hours +$0.11 (0.40%) Nov 3, 7:59 PM ET
About SUPN
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Company
- Headquarters
- Rockville, MD
- Employees
- 778 (2026)
- Listed
- May 1, 2012
- Exchange
- Nasdaq
- Website
- supernus.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #102 of 430
- P/B #165 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T-0.11%
- JNJJohnson & Johnson$640.8B-1.62%
- ABBVAbbVie Inc$505.4B-0.98%
- MRKMerck & Co Inc$356.9B-2.49%
- NVSNovartis AG$300.8B-1.40%
Financial summary
Related companies
About
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.